Alivus Life Sciences Ltd.

The company witnessed a 16.90% growth in the revenue at Rs. 5953.63 millions for the quarter ended September 2023 as compared to Rs. 5092.99 millions during the year-ago period.A humble growth in net profit of 11.10% reported in the quarter ended September 2023 to Rs. 1187.37  millions from Rs. 1068.78 millions.Operating profit for the quarter ended September 2023 rose to 1724.53 millions as compared to 1536.59 millions of corresponding quarter ended September 2022.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202309	202209	% Var	202309	202209	% Var	202303	202203	% Var
Sales	5953.63	5092.99	16.90	11738.13	9991.69	17.48	21612.20	21232.14	1.79
Other Income	53.69	100.20	-46.42	72.20	195.13	-63.00	289.57	147.04	96.93
PBIDT	1724.53	1536.59	12.23	3674.65	3099.20	18.57	6712.50	6307.64	6.42
Interest	3.99	1.33	200.00	7.95	2.68	196.64	5.47	279.62	-98.04
PBDT	1720.54	1535.26	12.07	3666.70	3096.52	18.41	6707.03	6028.02	11.26
Depreciation	131.29	99.35	32.15	257.41	198.14	29.91	420.94	378.77	11.13
PBT	1589.25	1435.91	10.68	3409.29	2898.38	17.63	6286.09	5649.25	11.27
TAX	401.88	367.13	9.47	867.42	742.27	16.86	1616.48	1462.01	10.57
Deferred Tax	14.88	28.20	-47.23	44.43	41.05	8.23	110.37	85.74	28.73
PAT	1187.37	1068.78	11.10	2541.87	2156.11	17.89	4669.61	4187.24	11.52
Equity	245.05	245.05	0.00	245.05	245.05	0.00	245.05	245.05	0.00
PBIDTM(%)	28.97	30.17	-3.99	31.31	31.02	0.93	31.06	29.71	4.55